Developer docs
API playgroundTry for free, no card

Search company profiles

Komipharm

Full company profile

uuid000r5ng

Namestring
Komipharm
Legal namestring
Komipharm International Co., Ltd.
Websiteurl
komipharm.co.kr
Company typeenum
Public
Founded yearint
1972
Descriptiontext

Komipharm International Co., Ltd. is a South Korea-based, KOSDAQ-listed animal health and pharmaceutical company founded in 1972 (originally as Komilab) and headquartered in Siheung-Si, Gyeonggi-Do. The company operates two divisions: an Animal Health division that manufactures veterinary vaccines (including the PRO-VAC series for swine, poultry, and bovine), antibiotics, antibacterial agents, nutritional supplements, and metabolic/immune enhancers under Korean Veterinary Good Manufacturing Practice (KVGMP) standards; and a Pharmaceutical division developing human therapeutics anchored by the proprietary anticancer candidate KML001 (sodium metaarsenite), a telomere/telomerase-targeting agent with published Phase I clinical trial data.

The company generates revenue through one-time sales of veterinary products distributed domestically via a network of over 130 Korean distribution agents and internationally via direct exports to 27 countries. A second revenue stream comes from per-test fees charged by KRSL (Komipharm Rabies Serology Laboratory), which performs WOAH/ANSES-certified rabies neutralization antibody testing for international pet travel, with veterinary hospitals registering clients and submitting samples through an online portal. R&D is run from a Central Research Institute (established 1998) with cooperative research networks spanning 8 domestic and 10 overseas institutes in the US and Europe. Manufacturing is conducted at two plants in Yesan-Gun, Chungcheongnam-Do and Cheongwon-Gun, Chungcheongbuk-Do.

The go-to-market model is hybrid: domestically, channel partners (130+ distributors) supply veterinary hospitals and livestock farmers; internationally, direct sales with multilingual support teams (English, Chinese, Russian, Spanish) engage foreign customers through exhibitions and seminars. KOSDAQ listing since 2001 mandates formal IR disclosures, with reported sales of KRW 349.9B (2018), KRW 362.9B (2019), and KRW 380.2B (2020). Customer concentration risk is dispersed across many small veterinary hospitals and livestock farmers in both domestic and export markets, with no single dominant customer identified in the dataset.

Short descriptiontext

Komipharm International Co., Ltd. is a South Korea-based, KOSDAQ-listed animal health pharmaceutical company that develops, manufactures, and exports veterinary vaccines, antibiotics, and supplements for livestock and companion animals across 27 countries, and operates a WOAH-certified rabies serology testing laboratory.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersSiheungodong, South Korea
HQ citystring
Siheungodong
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
veterinary vaccines, animal health products, rabies serology testing, livestock pharmaceuticals, anticancer drug development
Industry3 codes
PRIMARYHLAMAEAB
Livestock & Production Animal Therapeutics (Rx)
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Pharmaceuticals & Biologics
SECONDARYHLAMAEAE
Antimicrobials & Anti-infectives
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Pharmaceuticals & Biologics
SECONDARYHLAMADAC
Veterinary Microbiology & Infectious Disease Testing (Culture/PCR/Serology)
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Diagnostics (Labs & Imaging)
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Veterinary Services54194
SIC code3 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
  • Agricultural Prod-Livestock & Animal Specialties200
Product category
Animal Health / Veterinary Pharmaceuticals
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Veterinary Pharmaceuticals and Vaccines
TypeOne Time License
Description

Komipharm generates revenue primarily from the manufacture and sale of veterinary pharmaceuticals including vaccines (swine, avian, bovine, companion animal), chemical preparations, antibiotics, nutritional supplements, and metabolic/immune enhancers for livestock, aquaculture, and companion animals. Products are sold domestically through a network of 130+ distributors and exported to 27 countries globally.

komipharm.co.kr
2Human Anti-Cancer Drug Development
TypeOne Time License
Description

Revenue from the development and potential commercialization of novel anti-cancer drug candidates including KML001 (sodium metaarsenite), focused on therapeutic agents for cancer pain and autoimmune diseases based on anticancer drug platforms.

komipharm.co.kr
3Rabies Serology Laboratory Services (KRSL)
TypeTransaction Fee
Description

KRSL provides rabies neutralization antibody testing services for international pet travel certification. Testing is conducted via veterinary hospital registration through the KRSL online portal, with sample collection at animal hospitals, laboratory testing at Komipharm, and results/certificates delivered by post or courier. Fees are charged per test.

krsl.komipharm.co.kr
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Supply Chain, Operations, Technology or R&D, Personnel, Marketing or Sales
Pricing details1 tier
1Rabies serology testing is available on a per-test fee basis for pet owners through veterinary hospital referrals
ModelTransaction based/ take rateBilling cadencePay-as-you-go
Notes

Test fees are paid via virtual account payment or other online payment methods. Payment must be completed before sample processing. Results are delivered by registered mail (Korea Post) or courier (with additional courier fees borne by the requester).

krsl.komipharm.co.kr
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1KRSL
Description

Komipharm Rabies Serology Laboratory - central research institute providing officially certified rabies neutralization antibody testing services, recognized by France's ANSES Nancy Laboratory as a standard rabies research institute under the World Animal Health Organization (WOAH).

krsl.komipharm.co.kr
+2 more records
Core offering1 text field

Komipharm manufactures and sells veterinary vaccines (PRO-VAC series), antibiotics, antibacterial agents, nutritional supplements, and metabolic/immune enhancers for livestock (swine, poultry, bovine), aquaculture, and companion animals under KVGMP standards. The company also operates KRSL, a WOAH/ANSES-certified rabies neutralization antibody testing laboratory serving international pet travel certification, and maintains a pharmaceutical division developing novel anticancer drug candidates including KML001 (sodium metaarsenite).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Rabies neutralization antibody testing capacity: testing conducted twice weekly (Tuesday and Friday), with results available within approximately 2 weeks of sample receipt
+2 more records
Product overview1 text field

Komipharm International Co., Ltd. operates two main business divisions: Animal Health and Pharmaceutical. The Animal Health division produces a comprehensive range of veterinary products including vaccine preparations (PRO-VAC series), chemical preparations, and aquaculture products for swine, poultry, bovine, and companion animals. The company also operates KRSL (Komipharm Rabies Serology Laboratory), an officially certified rabies antibody testing center. The Pharmaceutical division focuses on anticancer drug development, including the KML001 candidate. The company maintains a Central Research Institute for R&D activities and offers diagnostic services through its Disease Diagnosis Center.

Product and service8 records
1PRO-VAC Series Veterinary Vaccines (Swine, Avian, Bovine)
CategoryVeterinary Vaccines
Description

Comprehensive line of veterinary vaccines for prevention of economically significant livestock diseases including Classical Swine Fever, Newcastle Disease, Avian Influenza, Infectious Bovine Rhinotracheitis, BVD, Porcine Circovirus type 2, and Salmonella. Targeted at livestock farmers and veterinary hospitals in South Korea and across 27 export markets.

2RES-VAC (Swine Respiratory Complex Vaccine)
CategoryVeterinary Vaccines
Description

Comprehensive swine respiratory vaccine effective against atrophic rhinitis, pasteurella pneumonia, mycoplasma pneumonia, pleuropneumonia, and Glasser's disease, designed to reduce vaccination frequency and pig stress. Targeted at swine farmers.

3Ecoro-VAC (E. coli Pilus Vaccine)
CategoryVeterinary Vaccines
Description

Bovine E. coli pilus vaccine for preventing calf scours, used in combination with Locovac vaccine for comprehensive protection in calves. Targeted at bovine farmers.

4H5-AINK (Avian Influenza + Newcastle Disease Vaccine)
CategoryVeterinary Vaccines
Description

Combined vaccine for prevention of Highly Pathogenic Avian Influenza (H5N1 and H5N6) and Newcastle Disease infection in chickens. Targeted at poultry farmers.

5Neguvon Solution (네구본질액) - Ectoparasiticide
CategoryVeterinary Pharmaceuticals
Description

Broad-spectrum ectoparasiticide and dermatological treatment for livestock used for scabies, mite infestations, ticks, fleas, and other external parasites. Targeted at livestock farmers.

6KRSL Rabies Neutralization Antibody Testing Service
CategoryVeterinary Diagnostic Laboratory Services
Description

Rabies neutralization antibody testing service, officially certified by France's ANSES Nancy Laboratory (the WOAH reference laboratory for rabies) as a rabies neutralization antibody testing institution. Testing conducted twice weekly (Tuesday and Friday), results reported within ~2 weeks, certificates issued for international pet travel / export. Targeted at veterinary hospitals and pet owners exporting animals internationally.

7Veterinary Chemical Preparations, Antibiotics, Nutritional Supplements and Metabolic/Immune Enhancers
CategoryVeterinary Pharmaceuticals
Description

Broad line of chemical preparations including antibiotics, antibacterial agents, nutritional supplements, and metabolic/immune enhancers for livestock, aquaculture, and companion animals, produced under KVGMP standards. Targeted at livestock farmers, aquaculture operators, companion animal owners, and veterinary hospitals.

8KML001 Anticancer Drug Candidate (Sodium Metaarsenite)
CategoryHuman Pharmaceutical R&D (Anticancer)
Description

Proprietary orally bioavailable arsenic compound (sodium metaarsenite) developed as an anticancer agent targeting telomeres and the catalytic subunit of telomerase (hTERT). Has undergone Phase I clinical trials (published in Clinical Cancer Research 2008, 14(14):4593-4602) and multiple in vitro/in vivo studies in prostate cancer, non-Hodgkin's lymphoma, and solid tumors. Targeted at human oncology research and licensing partners.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
18 Domestic Research Institutes (South Korea)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on1998-01-01
Description

Komipharm's R&D center established in 1998 has built a cooperative system with 8 domestic research institutes in South Korea, focusing on veterinary disease research and new product development including vaccine and anti-cancer drug development.

komipharm.co.kr
210 Overseas Research Institutes (America, Europe)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on1998-01-01
Description

Komipharm's R&D center has established cooperation with 10 overseas institutes in America and Europe for international new drug development, including vaccines and anti-cancer treatments, supporting the company's global bio-field leadership strategy.

komipharm.co.kr
3ANSES Nancy Laboratory (France)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

ANSES Nancy Laboratory, the World Animal Health Organization (WOAH) reference laboratory for rabies in France, officially certified Komipharm's KRSL (Rabies Serology Laboratory) as a rabies neutralization antibody testing institution. This certification enables KRSL to provide officially recognized rabies antibody testing for international pet travel.

krsl.komipharm.co.kr
Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

World's largest animal health company offering vaccines, parasiticides, and diagnostics across livestock and companion animals. Directly comparable to Komipharm's core veterinary vaccine and pharmaceutical portfolio, but at materially greater global scale.

2Boehringer Ingelheim Animal Health
TypeBroad incumbent
Description

Major multinational animal health player with a strong livestock vaccine portfolio (including swine and avian influenza). Comparable to Komipharm in product categories, with broader global reach and pipeline depth.

TypeBroad incumbent
Description

Global animal health division of Merck offering vaccines, anti-infectives, and parasiticides across livestock and companion animals. Competes with Komipharm in swine, poultry, and bovine vaccine markets internationally.

TypeDirect peer
Description

Independent global animal health company focused on vaccines, parasiticides, and pharmaceuticals for livestock and companion animals. Closely comparable mid-sized animal health peer with similar product mix and emerging market presence.

TypeDirect peer
Description

Global veterinary pharmaceutical company specializing in vaccines and pharmaceuticals for swine, poultry, and ruminants. Highly comparable in product categories and geographic emphasis on emerging markets.

TypeDirect peer
Description

Animal health and nutrition company focused on vaccines, parasiticides, and nutritional specialties for livestock. Comparable mid-tier competitor with similar livestock vaccine orientation.

TypeDirect peer
Description

Independent veterinary pharmaceutical company offering vaccines and pharmaceuticals for livestock and companion animals. Comparable in size and product mix to Komipharm's animal health division.

TypeRegional player
Description

Korean veterinary vaccine manufacturer focused on livestock and companion animals. Direct domestic Korean competitor to Komipharm with overlapping product categories and customer base.

TypeEmerging player
Description

Leader in companion animal diagnostics and testing services. Comparable to Komipharm's KRSL diagnostic/testing franchise in offering certified animal disease diagnostics, though focused on companion animal in-clinic testing rather than rabies serology.

TypeRegional player
Description

Korean veterinary vaccine and animal health products manufacturer. Regional peer competing with Komipharm in the domestic Korean market with overlapping livestock vaccine offerings.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Komipharm

Animal Health / Veterinary Pharmaceuticalskomipharm.co.kr

Komipharm International Co., Ltd. is a South Korea-based, KOSDAQ-listed animal health pharmaceutical company that develops, manufactures, and exports veterinary vaccines, antibiotics, and supplements for livestock and companion animals across 27 countries, and operates a WOAH-certified rabies serology testing laboratory.

What Komipharm does

Komipharm International Co., Ltd. is a South Korea-based, KOSDAQ-listed animal health and pharmaceutical company founded in 1972 (originally as Komilab) and headquartered in Siheung-Si, Gyeonggi-Do. The company operates two divisions: an Animal Health division that manufactures veterinary vaccines (including the PRO-VAC series for swine, poultry, and bovine), antibiotics, antibacterial agents, nutritional supplements, and metabolic/immune enhancers under Korean Veterinary Good Manufacturing Practice (KVGMP) standards; and a Pharmaceutical division developing human therapeutics anchored by the proprietary anticancer candidate KML001 (sodium metaarsenite), a telomere/telomerase-targeting agent with published Phase I clinical trial data.

The company generates revenue through one-time sales of veterinary products distributed domestically via a network of over 130 Korean distribution agents and internationally via direct exports to 27 countries. A second revenue stream comes from per-test fees charged by KRSL (Komipharm Rabies Serology Laboratory), which performs WOAH/ANSES-certified rabies neutralization antibody testing for international pet travel, with veterinary hospitals registering clients and submitting samples through an online portal. R&D is run from a Central Research Institute (established 1998) with cooperative research networks spanning 8 domestic and 10 overseas institutes in the US and Europe. Manufacturing is conducted at two plants in Yesan-Gun, Chungcheongnam-Do and Cheongwon-Gun, Chungcheongbuk-Do.

The go-to-market model is hybrid: domestically, channel partners (130+ distributors) supply veterinary hospitals and livestock farmers; internationally, direct sales with multilingual support teams (English, Chinese, Russian, Spanish) engage foreign customers through exhibitions and seminars. KOSDAQ listing since 2001 mandates formal IR disclosures, with reported sales of KRW 349.9B (2018), KRW 362.9B (2019), and KRW 380.2B (2020). Customer concentration risk is dispersed across many small veterinary hospitals and livestock farmers in both domestic and export markets, with no single dominant customer identified in the dataset.

Komipharm firmographics

Firmographics
Name
Komipharm
Legal name
Komipharm International Co., Ltd.
Website
https://komipharm.co.kr
Company type
Public
Founded year
1972
Operating status
Operating
Headcount range
101–250 employees
Short description
Komipharm International Co., Ltd. is a South Korea-based, KOSDAQ-listed animal health pharmaceutical company that develops, manufactures, and exports veterinary vaccines, antibiotics, and supplements for livestock and companion animals across 27 countries, and operates a WOAH-certified rabies serology testing laboratory.
Ownership category
akta.pro rank

Komipharm industry classification

Industry
Product category
Animal Health / Veterinary Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Veterinary Services (54194)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Agricultural Prod-Livestock & Animal Specialties (200)
akta.pro industry
PRIMARYHLAMAEAB
Livestock & Production Animal Therapeutics (Rx)
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Pharmaceuticals & Biologics
SECONDARYHLAMAEAE
Antimicrobials & Anti-infectives
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Pharmaceuticals & Biologics
SECONDARYHLAMADAC
Veterinary Microbiology & Infectious Disease Testing (Culture/PCR/Serology)
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Diagnostics (Labs & Imaging)

Keywords

  • Veterinary vaccines
  • Animal health products
  • Rabies serology testing
  • Livestock pharmaceuticals
  • Anticancer drug development

Where Komipharm is headquartered

Location

Headquarters

HQ city
Siheungodong
HQ country
South Korea
HQ region
Asia

Offices4 records

Markets served

Komipharm business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Technology or R&D, Personnel, Marketing or Sales

Revenue model

  1. Veterinary Pharmaceuticals and Vaccines: Komipharm generates revenue primarily from the manufacture and sale of veterinary pharmaceuticals including vaccines (swine, avian, bovine, companion animal), chemical preparations, antibiotics, nutritional supplements, and metabolic/immune enhancers for livestock, aquaculture, and companion animals. Products are sold domestically through a network of 130+ distributors and exported to 27 countries globally.
  2. Human Anti-Cancer Drug Development: Revenue from the development and potential commercialization of novel anti-cancer drug candidates including KML001 (sodium metaarsenite), focused on therapeutic agents for cancer pain and autoimmune diseases based on anticancer drug platforms.
  3. Rabies Serology Laboratory Services (KRSL): KRSL provides rabies neutralization antibody testing services for international pet travel certification. Testing is conducted via veterinary hospital registration through the KRSL online portal, with sample collection at animal hospitals, laboratory testing at Komipharm, and results/certificates delivered by post or courier. Fees are charged per test.

Pricing tiers

ModelBillingPrice
Transaction based/ take ratePay-as-you-goRabies serology testing is available on a per-test fee basis for pet owners through veterinary hospital referrals

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Komipharm product offering

Product offering

Core offering

Komipharm manufactures and sells veterinary vaccines (PRO-VAC series), antibiotics, antibacterial agents, nutritional supplements, and metabolic/immune enhancers for livestock (swine, poultry, bovine), aquaculture, and companion animals under KVGMP standards. The company also operates KRSL, a WOAH/ANSES-certified rabies neutralization antibody testing laboratory serving international pet travel certification, and maintains a pharmaceutical division developing novel anticancer drug candidates including KML001 (sodium metaarsenite).

Product overview

Komipharm International Co., Ltd. operates two main business divisions: Animal Health and Pharmaceutical. The Animal Health division produces a comprehensive range of veterinary products including vaccine preparations (PRO-VAC series), chemical preparations, and aquaculture products for swine, poultry, bovine, and companion animals. The company also operates KRSL (Komipharm Rabies Serology Laboratory), an officially certified rabies antibody testing center. The Pharmaceutical division focuses on anticancer drug development, including the KML001 candidate. The company maintains a Central Research Institute for R&D activities and offers diagnostic services through its Disease Diagnosis Center.

Differentiator

Problem solved

Functional benefit

Brands

  • KRSL: Komipharm Rabies Serology Laboratory - central research institute providing officially certified rabies neutralization antibody testing services, recognized by France's ANSES Nancy Laboratory as a standard rabies research institute under the World Animal Health Organization (WOAH).
  • PRO-VAC
  • KML001

Products and services

  • PRO-VAC Series Veterinary Vaccines (Swine, Avian, Bovine) Comprehensive line of veterinary vaccines for prevention of economically significant livestock diseases including Classical Swine Fever, Newcastle Disease, Avian Influenza, Infectious Bovine Rhinotracheitis, BVD, Porcine Circovirus type 2, and Salmonella. Targeted at livestock farmers and veterinary hospitals in South Korea and across 27 export markets.
  • RES-VAC (Swine Respiratory Complex Vaccine) Comprehensive swine respiratory vaccine effective against atrophic rhinitis, pasteurella pneumonia, mycoplasma pneumonia, pleuropneumonia, and Glasser's disease, designed to reduce vaccination frequency and pig stress. Targeted at swine farmers.
  • Ecoro-VAC (E. coli Pilus Vaccine) Bovine E. coli pilus vaccine for preventing calf scours, used in combination with Locovac vaccine for comprehensive protection in calves. Targeted at bovine farmers.
  • H5-AINK (Avian Influenza + Newcastle Disease Vaccine) Combined vaccine for prevention of Highly Pathogenic Avian Influenza (H5N1 and H5N6) and Newcastle Disease infection in chickens. Targeted at poultry farmers.
  • Neguvon Solution (네구본질액) - Ectoparasiticide Broad-spectrum ectoparasiticide and dermatological treatment for livestock used for scabies, mite infestations, ticks, fleas, and other external parasites. Targeted at livestock farmers.
  • KRSL Rabies Neutralization Antibody Testing Service Rabies neutralization antibody testing service, officially certified by France's ANSES Nancy Laboratory (the WOAH reference laboratory for rabies) as a rabies neutralization antibody testing institution. Testing conducted twice weekly (Tuesday and Friday), results reported within ~2 weeks, certificates issued for international pet travel / export. Targeted at veterinary hospitals and pet owners exporting animals internationally.
  • Veterinary Chemical Preparations, Antibiotics, Nutritional Supplements and Metabolic/Immune Enhancers Broad line of chemical preparations including antibiotics, antibacterial agents, nutritional supplements, and metabolic/immune enhancers for livestock, aquaculture, and companion animals, produced under KVGMP standards. Targeted at livestock farmers, aquaculture operators, companion animal owners, and veterinary hospitals.
  • KML001 Anticancer Drug Candidate (Sodium Metaarsenite) Proprietary orally bioavailable arsenic compound (sodium metaarsenite) developed as an anticancer agent targeting telomeres and the catalytic subunit of telomerase (hTERT). Has undergone Phase I clinical trials (published in Clinical Cancer Research 2008, 14(14):4593-4602) and multiple in vitro/in vivo studies in prostate cancer, non-Hodgkin's lymphoma, and solid tumors. Targeted at human oncology research and licensing partners.

Quantifiable outcome

  • Rabies neutralization antibody testing capacity: testing conducted twice weekly (Tuesday and Friday), with results available within approximately 2 weeks of sample receipt
  • +2 more outcomes

Companies that use Komipharm

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Komipharm technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Komipharm partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • 8 Domestic Research Institutes (South Korea)coreStrategic or Co-development Partner · 1 January 1998Komipharm's R&D center established in 1998 has built a cooperative system with 8 domestic research institutes in South Korea, focusing on veterinary disease research and new product development including vaccine and anti-cancer drug development.
  • 10 Overseas Research Institutes (America, Europe)coreStrategic or Co-development Partner · 1 January 1998Komipharm's R&D center has established cooperation with 10 overseas institutes in America and Europe for international new drug development, including vaccines and anti-cancer treatments, supporting the company's global bio-field leadership strategy.
  • ANSES Nancy Laboratory (France)coreStrategic or Co-development PartnerANSES Nancy Laboratory, the World Animal Health Organization (WOAH) reference laboratory for rabies in France, officially certified Komipharm's KRSL (Rabies Serology Laboratory) as a rabies neutralization antibody testing institution. This certification enables KRSL to provide officially recognized rabies antibody testing for international pet travel.

Scale indicators6 records

Recent moves9 records

Expansion highlights5 records

Komipharm competitors and assessment

Company assessment

Broad incumbents

  • Zoetis: World's largest animal health company offering vaccines, parasiticides, and diagnostics across livestock and companion animals. Directly comparable to Komipharm's core veterinary vaccine and pharmaceutical portfolio, but at materially greater global scale.
  • Boehringer Ingelheim Animal Health: Major multinational animal health player with a strong livestock vaccine portfolio (including swine and avian influenza). Comparable to Komipharm in product categories, with broader global reach and pipeline depth.
  • Merck Animal Health: Global animal health division of Merck offering vaccines, anti-infectives, and parasiticides across livestock and companion animals. Competes with Komipharm in swine, poultry, and bovine vaccine markets internationally.

Direct peers

  • Virbac: Independent global animal health company focused on vaccines, parasiticides, and pharmaceuticals for livestock and companion animals. Closely comparable mid-sized animal health peer with similar product mix and emerging market presence.
  • Ceva Santé Animale: Global veterinary pharmaceutical company specializing in vaccines and pharmaceuticals for swine, poultry, and ruminants. Highly comparable in product categories and geographic emphasis on emerging markets.
  • Phibro Animal Health: Animal health and nutrition company focused on vaccines, parasiticides, and nutritional specialties for livestock. Comparable mid-tier competitor with similar livestock vaccine orientation.
  • Vetoquinol: Independent veterinary pharmaceutical company offering vaccines and pharmaceuticals for livestock and companion animals. Comparable in size and product mix to Komipharm's animal health division.

Regional players

  • Choong Ang Vaccine Laboratories: Korean veterinary vaccine manufacturer focused on livestock and companion animals. Direct domestic Korean competitor to Komipharm with overlapping product categories and customer base.
  • KBNP (Korea BNP): Korean veterinary vaccine and animal health products manufacturer. Regional peer competing with Komipharm in the domestic Korean market with overlapping livestock vaccine offerings.

Emerging players

  • IDEXX Laboratories: Leader in companion animal diagnostics and testing services. Comparable to Komipharm's KRSL diagnostic/testing franchise in offering certified animal disease diagnostics, though focused on companion animal in-clinic testing rather than rabies serology.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Komipharm financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Komipharm leadership team

Management profile

Number of profiles

Profiles6 records

Komipharm subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Komipharm funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Komipharm M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Komipharm

What does Komipharm do?

Komipharm manufactures and sells veterinary vaccines (PRO-VAC series), antibiotics, antibacterial agents, nutritional supplements, and metabolic/immune enhancers for livestock (swine, poultry, bovine), aquaculture, and companion animals under KVGMP standards. The company also operates KRSL, a WOAH/ANSES-certified rabies neutralization antibody testing laboratory serving international pet travel certification, and maintains a pharmaceutical division developing novel anticancer drug candidates including KML001 (sodium metaarsenite).

Is Komipharm a public or private company?

Komipharm is a public company. It is classified as public and is currently operating.

When was Komipharm founded?

Komipharm was founded in 1972. It employs 101 to 250 people.

Where is Komipharm based?

Komipharm is headquartered in Siheungodong, South Korea, in the Asia region.

How does Komipharm make money?

Three revenue lines are on record. Veterinary Pharmaceuticals and Vaccines are the primary driver. The others are human Anti-Cancer Drug Development and rabies Serology Laboratory Services (KRSL).

Who are Komipharm's main competitors?

Broad incumbents on record are Zoetis, Boehringer Ingelheim Animal Health and Merck Animal Health. Direct peers are Virbac, Ceva Santé Animale, Phibro Animal Health and Vetoquinol. Regional players are Choong Ang Vaccine Laboratories and KBNP (Korea BNP). IDEXX Laboratories is listed as an emerging player.

Does Komipharm have an API?

No public API is recorded for Komipharm.

What industry is Komipharm in?

Komipharm's product category is Animal Health / Veterinary Pharmaceuticals. Its primary akta.pro industry code is HLAMAEAB, Livestock & Production Animal Therapeutics (Rx), with a secondary code of HLAMAEAE, Antimicrobials & Anti-infectives. Its NAICS code is 325412 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals